Duloxetine Recall: Important Information for Patients

Duloxetine Recall: Important Information for Patients

A well-known antidepressant is currently under recall due to potential contamination with a cancer-causing compound. Breckenridge Pharmaceuticals, a company based in New Jersey, is recalling bottles of duloxetine, a generic version of Cymbalta, which is commonly used to treat depression, anxiety, and fibromyalgia. The U.S. Food and Drug Administration discovered elevated levels of "N-nitroso-duloxetine" in the delayed-release capsules, prompting the recall of specific lots distributed across the country.

The recall affects certain lots of 30mg and 60mg duloxetine delayed-release capsules with expiration dates ranging from February 2026 to April 2027. Patients who have these recalled medications are urged to contact their healthcare provider or pharmacist for guidance on the next steps. It is essential for patients not to discontinue the medication without consulting their doctor first to ensure proper management of their condition.

Nitrosamines are potentially harmful compounds that can develop during the production, storage, or packaging of certain medications. Exposure to nitrosamine impurities above acceptable levels over an extended period may increase the risk of cancer. Patients should prioritize their health and safety by following the recall guidelines and seeking medical advice to address any concerns related to the recalled antidepressant.

In conclusion, the recall of duloxetine capsules highlights the importance of pharmaceutical quality control and patient safety. Patients should remain vigilant about medication recalls and promptly address any issues with their healthcare providers to ensure optimal treatment outcomes and minimize potential health risks.